Prevention of Transmission of Virus Infections by Blood Transfusions and Removal of Virus Infectivity from Clotting Factor Concentrates
Virus infections are serious complications following blood transfusions or intravenous therapy with clotting factor concentrates. Hepatitis A virus (HAV) is rarely transmitted by blood and never by plasma derivatives. Hepatitis A is characterized by a short viremia which most often coincides with clinical illness. In addition neutralizing antibodies to HAV are present in all plasma pools from which clotting factor concentrates are manufactured (1). Chronic Hepatitis B and non-A non-B hepatitis commonly follow acute infections (5 to 10% for hepatitis B, more than 40% and perhaps close to 100% for non-A non-B hepatitis). Chronic infections with hepatitis B virus (HBV) are characterized by serum levels of infectious virus up to 108/ml (infectious units) while levels of infectious non-A non-B virus are generally in the range of 102/ml (2,3). Little has been published concerning levels of HTLV III in blood or plasma.
KeywordsSaccharose Hepatitis Albumin Citrate Chloroform
Unable to display preview. Download preview PDF.
- 3.Tabor E. Propagation of hepatitis viruses in vivo and in vitro: Viral Hepatitis: Second International Max von Pettenkofer Symposium, Overby LR, Deinhardt F, Deinhardt J, Dekker M, ed. New York 1983: 57–9.Google Scholar
- 5.Gerety RJ, Eyster ME. Hepatitis among hemophiliacs. In: Gerety RJ ed. Non-A, Non-B Hepatitis. New York, Academic Press 1981: 97–117.Google Scholar
- 6.Einarrson M. Studies on the hepatitis B virus. Isolation of hepatitis B surface antigen from human serum and removal of hepatitis B virus from blood products. Doctoral thesis; Uppsala University, KabiVitrum AB, 112 87 Stockholm, Sweden 1983.Google Scholar
- 8.Murray R. Viral hepatitis Bull. N.Y. Acad. Med, 1985; 31: 341–58.Google Scholar
- 10.Gellis SS, Neefe JR, Stokes J, Strong LE, Janeway CA, Scatchard G. Chemical, clinical and immunological studies on the products of human plasma fractionation XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 1948; 27: 239–44.CrossRefGoogle Scholar
- 12.Tabor E, Gerety RJ. The chimpanzee animal model for non-A, non-B hepatitis: New application. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis: 1981 International Symposium. Phila.: Franklin Institute Press, 1982: 305 - 17.Google Scholar
- 13.Seto B, Coleman Jr. WG, Iwarson S, Gerety RJ. Detection of reverse transcriptase activity in association with the non-A, non-B hepatitis agent(s). Lancet 1984;ii:941–3.Google Scholar
- 14.Soulier JP, Blatix C, Courouce AM, Benamon D, Amouch P, Drouet J. Prevention of virus B hepatitis ( SH hepatitis ). A J Dis Child, 1972: 429–34.Google Scholar